Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials
- 10 October 2012
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 9 (5), 578-587
- https://doi.org/10.1177/1740774512456454
Abstract
The sequential parallel comparison (SPC) design was proposed to improve the efficiency of psychiatric clinical trials by reducing the impact of placebo response. It consists of two consecutive placebo-controlled comparisons of which the second is only entered by placebo nonresponders from the first. Previous studies suggest that in antidepressant trials, nonresponse to placebo can already be predicted after 2 weeks of follow-up. This would allow to reduce the first phase of the SPC design to further increase its efficiency. To compare the sample size requirements of an 8-week randomized controlled trial (RCT8) and alternative SPC designs with equal or longer total follow-up duration (SPC2+6, SPC4+4, and SPC6+6). Scenarios for response and dropout rates were defined. Sample sizes to achieve 80% power were determined for the various designs. Three treatment functions assumed either a smaller, equal, or larger effect at the early stage of the trial as compared with that at the end. Two dropout models described either predominantly early or linearly increasing dropout, and dropout was considered as nonresponse. The relative efficiency of the different designs was evaluated across these scenarios and for a specific scenario based on empirical antidepressant trial data. The different SPC designs (i.e., SPC2+6, SPC4+4, and SPC6+6) were generally more efficient than the RCT8 design when the treatment effect at the early stage of the trial was equal or larger than the effect at the end. In this case, the advantage of the SPC designs increased in the presence of dropout. The SPC2+6 design was usually more efficient than the SPC4+4 design and was relatively less affected by dropout when it occurred predominantly early. For the scenario that was based on antidepressant trial data, the SPC2+6 and SPC4+4 designs required 51% and 53% fewer patients than the RCT8 design. A limited variety of scenarios was evaluated. Parameter values resembled those observed in antidepressant trials. This study suggests that SPC designs are highly efficient alternatives to a conventional RCT in indications where placebo response is high and substantial treatment effects are established after a relatively short follow-up period (i.e., after the first SPC design phase). We conclude that SPC designs can reduce sample size requirements and increase success rates of antidepressant trials.Keywords
This publication has 19 references indexed in Scilit:
- L-methylfolate augmentation of selective serotonin reuptake inhibitors (SSRIS) for major depressive disorder: Results of two randomized, double-blind trialsEuropean Psychiatry, 2011
- Does early improvement triggered by antidepressants predict response/remission? — Analysis of data from a naturalistic study on a large sample of inpatients with major depressionJournal of Affective Disorders, 2009
- The State of Innovation in Drug DevelopmentClinical Pharmacology & Therapeutics, 2008
- An examination of the efficiency of the sequential parallel design in psychiatric clinical trialsClinical Trials, 2007
- Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trialsBritish Journal of Clinical Pharmacology, 2007
- Placebo response in clinical trials of depression and its implications for research on chronic neuropathic painNeurology, 2005
- The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design ApproachPsychotherapy and Psychosomatics, 2003
- The Sequential Parallel Comparison Model: A Revolution in the Design of Clinical TrialsPsychotherapy and Psychosomatics, 2003
- Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval ReportsNeuropsychopharmacology, 2002
- Concerns About Clinical Drug TrialsJournal of Clinical Psychopharmacology, 2000